AnaptysBio
ANAB
46.63
-0.77
-1.62%
AnaptysBio
US · ANAB
#3010 by market cap
Listed 2017
46.63
-0.77
-1.62%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Recent news
-
Rating change
TD Cowen Maintains AnaptysBio(ANAB.US) With Buy RatingMarket Newswire · 2026/8/25
-
Rating change
TD Cowen Maintains AnaptysBio(ANAB.US) With Buy Rating, Cuts Target Price to $70Market Newswire · 2026/8/25
-
Rating change
A Quick Look at Today's Ratings for AnaptysBio(ANAB.US), With a Forecast Between $75 to $93Market Newswire · 2026/5/13
-
Rating change
TD Cowen Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $75Market Newswire · 2026/7/13
-
Rating change
UBS Maintains AnaptysBio(ANAB.US) With Buy Rating, Raises Target Price to $76Market Newswire · 2026/5/13
-
Rating change
Piper Sandler Maintains AnaptysBio(ANAB.US) With Buy Rating, Cuts Target Price to $93Market Newswire · 2026/5/4
-
Rating change
Leerink Partners Maintains AnaptysBio(ANAB.US) With Buy Rating, Raises Target Price to $90Market Newswire · 2026/5/15
-
Rating change
J.P. Morgan Maintains AnaptysBio(ANAB.US) With Buy Rating, Raises Target Price to $70Market Newswire · 2026/5/23
-
Rating change
H.C. Wainwright Initiates AnaptysBio(ANAB.US) With Buy Rating, Announces Target Price $95Market Newswire · 2026/6/10
-
Rating change
Leerink Partners Maintains AnaptysBio(ANAB.US) With Buy RatingMarket Newswire · 2026/5/27
-
Rating change
Leerink Partners Maintains AnaptysBio(ANAB.US) With Buy Rating, Announces Target Price $85Market Newswire · 2026/4/28
-
H.C. Wainwright Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $95Market Newswire · 2026/11/13
-
Leerink Partners Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $81Market Newswire · 2026/10/22
-
Company notice
AnaptysBio: Anaptys Biosciences, Inc. - Distribution Option Symbol: ANAB New Symbol: ANAB1OCC · 2026/4/7
-
Piper Sandler Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $93Market Newswire · 2026/11/13
-
Rating change
UBS Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $76Market Newswire · 2026/9/22
-
Rating change
Leerink Partners Maintains AnaptysBio(ANAB.US) With Buy Rating, Announces Target Price $81Market Newswire · 2026/9/23
-
Barclays Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $75Market Newswire · 2026/11/14
-
Earnings Flash (ANAB) AnaptysBio, Inc. Reports Q1 Revenue $30.3M, Vs. FactSet Est of $18.9MMT Newswires · 2026/11/13
-
Rating change
J.P. Morgan Maintains AnaptysBio(ANAB.US) With Buy Rating, Cuts Target Price to $60Market Newswire · 2026/9/30
-
Rating change
TD Cowen Maintains AnaptysBio(ANAB.US) With Buy Rating, Announces Target Price $75Market Newswire · 2026/4/27
-
Rating change
Piper Sandler Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $93Market Newswire · 2026/7/22
-
H.C. Wainwright Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $95Market Newswire · 2026/10/26
-
Rating change
Barclays Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $75Market Newswire · 2026/9/23
-
H.C. Wainwright Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $95Market Newswire · 2026/10/5
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
AnaptysBio discussion 0 comments